Science, Art, Litt, Science based Art & Science Communication
Trump, 74, received a single dose of Regeneron's antibody cocktail for his COVD 19 condition. What is it actually? Several people are asking me this Q.
According to the news release (1) by the people working on it ....
"REGN-COV2 is a combination of two monoclonal antibodies (REGN10933 and REGN10987) and was designed specifically to block infectivity of SARS-CoV-2, the virus that causes COVID-19.
To develop REGN-COV2, Regeneron scientists evaluated thousands of fully-human antibodies produced by the company's VelocImmune® mice, which have been genetically modified to have a human immune system, as well as antibodies identified from humans who have recovered from COVID-19. The two potent, virus-neutralizing antibodies that form REGN-COV2 bind non-competitively to the critical receptor binding domain of the virus's spike protein, which diminishes the ability of mutant viruses to escape treatment and protects against spike variants that have arisen in the human population, as detailed in Science. Preclinical studies have shown that REGN-COV2 reduced the amount of virus and associated damage in the lungs of non-human primates."
The treatment is undergoing clinical trials but hasn't yet received any form of regulatory approval(2).
Therefore what we know about this treatment's efficacy is not an established fact and can be viewed by clicking on ref.1 link.
Regeneron announced results from one of its early-stage trials which showed its drug, which is infused intravenously, reduced viral load and recovery time in non-hospitalized COVID-19 patients (2).
The US biotech firm is concurrently running late-stage trials for hospitalized COVID-19 patients and for the drug's potential use as a prophylactic.
Antibodies are infection-fighting proteins made by the immune system that can bind to particular structures on the surfaces of pathogens and prevent them from invading cells. Vaccines work by teaching the body to make its own antibodies, while scientists are also testing ready-made antibodies from the blood of recovered patients, called convalescent plasma. But it is not possible to make convalescent plasma a mass treatment. Researchers can also comb through the antibodies produced by recovered patients and select the most effective out of thousands, and then manufacture them at scale.
Regeneron's experimental Covid-19 drug, called REGN-COV2, is a combination of two antibodies, referred to as a "cocktail." The idea is that it will have a better chance at working if the virus mutates in order to evade the blocking action of a single antibody.